Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by palinc2000on Mar 02, 2023 12:31pm
60 Views
Post# 35315389

RE:RE:RE:RE:Tinfoil Hat

RE:RE:RE:RE:Tinfoil Hat

They did not hint they were on track they confirmed
 

As our first quarter is ending today, I can confirm that we are happy with unit sales for the quarter and that we are on track to meet our recently announced guidance of $90 million to $95 million, representing growth of approximately 13% to 19%

Wino115 wrote: Levesque spoke about the share price on the call, which he normally doesn't do, so it's a focus for sure. The short term is dictated by sales and growth in commercial. The other stuff is mid term if ever. They hinted the quarter was "on track" according to Dubuc, so somewhere in that estimated range.

I think we won't really see a move based off the revenue target until they actually report that kind of Y0Y and QoQ growth that reassures the $90mil rev and breakeven looks to be going in that direction. First quarter we will see if those words are right. Then maybe some of those value hunters will appear and the trend may turn toward it's inherant value level, whatever that is. But it's definitely not under $1.

 

<< Previous
Bullboard Posts
Next >>